vs

Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Waters Corporation (WAT). Click either name above to swap in a different company.

APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $932.4M, roughly 1.0× Waters Corporation). Waters Corporation runs the higher net margin — 24.2% vs 7.7%, a 16.4% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs 6.8%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs 2.6%).

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

ATR vs WAT — Head-to-Head

Bigger by revenue
ATR
ATR
1.0× larger
ATR
$962.7M
$932.4M
WAT
Growing faster (revenue YoY)
ATR
ATR
+6.7% gap
ATR
13.5%
6.8%
WAT
Higher net margin
WAT
WAT
16.4% more per $
WAT
24.2%
7.7%
ATR
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
2.6%
ATR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATR
ATR
WAT
WAT
Revenue
$962.7M
$932.4M
Net Profit
$74.3M
$225.2M
Gross Margin
61.1%
Operating Margin
11.0%
29.0%
Net Margin
7.7%
24.2%
Revenue YoY
13.5%
6.8%
Net Profit YoY
-26.4%
-2.7%
EPS (diluted)
$1.13
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATR
ATR
WAT
WAT
Q4 25
$962.7M
$932.4M
Q3 25
$961.1M
$799.9M
Q2 25
$966.0M
$771.3M
Q1 25
$887.3M
$661.7M
Q4 24
$848.1M
$872.7M
Q3 24
$909.3M
$740.3M
Q2 24
$910.1M
$708.5M
Q1 24
$915.4M
$636.8M
Net Profit
ATR
ATR
WAT
WAT
Q4 25
$74.3M
$225.2M
Q3 25
$127.9M
$148.9M
Q2 25
$111.7M
$147.1M
Q1 25
$78.8M
$121.4M
Q4 24
$100.9M
$231.4M
Q3 24
$100.0M
$161.5M
Q2 24
$90.5M
$142.7M
Q1 24
$83.1M
$102.2M
Gross Margin
ATR
ATR
WAT
WAT
Q4 25
61.1%
Q3 25
59.0%
Q2 25
58.3%
Q1 25
58.2%
Q4 24
60.1%
Q3 24
59.3%
Q2 24
59.3%
Q1 24
58.9%
Operating Margin
ATR
ATR
WAT
WAT
Q4 25
11.0%
29.0%
Q3 25
14.2%
24.0%
Q2 25
14.9%
24.4%
Q1 25
12.8%
22.9%
Q4 24
14.2%
33.5%
Q3 24
15.2%
28.5%
Q2 24
13.8%
26.7%
Q1 24
12.2%
21.0%
Net Margin
ATR
ATR
WAT
WAT
Q4 25
7.7%
24.2%
Q3 25
13.3%
18.6%
Q2 25
11.6%
19.1%
Q1 25
8.9%
18.3%
Q4 24
11.9%
26.5%
Q3 24
11.0%
21.8%
Q2 24
9.9%
20.1%
Q1 24
9.1%
16.0%
EPS (diluted)
ATR
ATR
WAT
WAT
Q4 25
$1.13
$3.76
Q3 25
$1.92
$2.50
Q2 25
$1.67
$2.47
Q1 25
$1.17
$2.03
Q4 24
$1.48
$3.88
Q3 24
$1.48
$2.71
Q2 24
$1.34
$2.40
Q1 24
$1.23
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATR
ATR
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$409.5M
$587.8M
Total DebtLower is stronger
$1.1B
$1.4B
Stockholders' EquityBook value
$2.7B
$2.6B
Total Assets
$5.3B
$5.1B
Debt / EquityLower = less leverage
0.43×
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATR
ATR
WAT
WAT
Q4 25
$409.5M
$587.8M
Q3 25
$264.8M
$459.1M
Q2 25
$169.8M
$367.2M
Q1 25
$136.8M
$382.9M
Q4 24
$226.2M
$325.4M
Q3 24
$327.9M
$331.5M
Q2 24
$223.9M
$327.4M
Q1 24
$201.1M
$338.2M
Total Debt
ATR
ATR
WAT
WAT
Q4 25
$1.1B
$1.4B
Q3 25
$546.0M
Q2 25
$535.1M
Q1 25
$561.2M
Q4 24
$688.1M
$1.6B
Q3 24
$822.7M
Q2 24
$681.5M
Q1 24
$680.4M
Stockholders' Equity
ATR
ATR
WAT
WAT
Q4 25
$2.7B
$2.6B
Q3 25
$2.8B
$2.3B
Q2 25
$2.7B
$2.2B
Q1 25
$2.5B
$2.0B
Q4 24
$2.5B
$1.8B
Q3 24
$2.5B
$1.6B
Q2 24
$2.4B
$1.4B
Q1 24
$2.3B
$1.3B
Total Assets
ATR
ATR
WAT
WAT
Q4 25
$5.3B
$5.1B
Q3 25
$5.1B
$4.9B
Q2 25
$4.9B
$4.7B
Q1 25
$4.5B
$4.6B
Q4 24
$4.4B
$4.6B
Q3 24
$4.6B
$4.5B
Q2 24
$4.5B
$4.4B
Q1 24
$4.4B
$4.5B
Debt / Equity
ATR
ATR
WAT
WAT
Q4 25
0.43×
0.55×
Q3 25
0.20×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.28×
0.89×
Q3 24
0.32×
Q2 24
0.28×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATR
ATR
WAT
WAT
Operating Cash FlowLast quarter
$183.7M
$164.6M
Free Cash FlowOCF − Capex
$96.9M
FCF MarginFCF / Revenue
10.1%
Capex IntensityCapex / Revenue
9.0%
Cash ConversionOCF / Net Profit
2.47×
0.73×
TTM Free Cash FlowTrailing 4 quarters
$299.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATR
ATR
WAT
WAT
Q4 25
$183.7M
$164.6M
Q3 25
$177.6M
$187.3M
Q2 25
$126.0M
$41.1M
Q1 25
$82.7M
$259.6M
Q4 24
$178.2M
$240.1M
Q3 24
$229.3M
$204.6M
Q2 24
$143.6M
$54.5M
Q1 24
$92.3M
$262.9M
Free Cash Flow
ATR
ATR
WAT
WAT
Q4 25
$96.9M
Q3 25
$114.3M
Q2 25
$62.5M
Q1 25
$25.9M
Q4 24
$112.2M
Q3 24
$162.7M
Q2 24
$75.4M
Q1 24
$16.7M
FCF Margin
ATR
ATR
WAT
WAT
Q4 25
10.1%
Q3 25
11.9%
Q2 25
6.5%
Q1 25
2.9%
Q4 24
13.2%
Q3 24
17.9%
Q2 24
8.3%
Q1 24
1.8%
Capex Intensity
ATR
ATR
WAT
WAT
Q4 25
9.0%
Q3 25
6.6%
Q2 25
6.6%
Q1 25
6.4%
Q4 24
7.8%
Q3 24
7.3%
Q2 24
7.5%
Q1 24
8.3%
Cash Conversion
ATR
ATR
WAT
WAT
Q4 25
2.47×
0.73×
Q3 25
1.39×
1.26×
Q2 25
1.13×
0.28×
Q1 25
1.05×
2.14×
Q4 24
1.77×
1.04×
Q3 24
2.29×
1.27×
Q2 24
1.59×
0.38×
Q1 24
1.11×
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATR
ATR

Pharma Segment$833.1M87%
Other$129.6M13%

WAT
WAT

Segment breakdown not available.

Related Comparisons